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Introduction 
Inflammatory bowel diseases (IBD) are pathologies characterized by a chronic inflamma-
tion of the gastrointestinal tract that present with abdominal pain and severe watery and 
bloody diarrhea. The most common inflammatory bowel diseases are Crohn’s disease 
(CD) and ulcerative colitis (UC).  
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SUMMARY 
Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, are pa-
thologies characterized by a chronic inflammation of the gastrointestinal tract. Their 
etiopathogenesis is not yet fully understood. Immune system and heat shock proteins  
(Hsps) dysfunctions are considered to be among the most likely causes of these diseases. 
Butyrate is a short-chain fatty acid mainly produced by intestinal microflora. It has a tro-
phic, beneficial and protective role in the colonic mucosa, and it also induces changes in 
Hsp levels and localization. It may therefore be a valuable complementary therapeutic 
agent when used alongside traditional drugs (mesalazine and corticosteroids) to treat 
such conditions. The administration of specific probiotic formulations in order to increase 
the production of butyrate in the endoluminal environment may promote clinical remis-
sion in IBD patients. Due to these characteristics, there has been keen interest in the use 
of  butyrate as a novel therapeutic supplement in the recent years. The current findings 
need to be validated through further clinical trials to better define the biomolecular dy-
namics of butyrate in the colonocytes of IBD patients. 
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IBDs are characterized by an early onset 
and extraintestinal manifestations, such as 
rheumatoid arthritis (1, 2). CD can affect 
any part of the gastrointestinal tract, on 
the contrary of UC, which is usually con-
fined to the colon and rectum. The inci-
dence of IBD in Europe and North America 
is 20/100000 inhabitants, indicating a link 
between such pathologies and the social 
and economic development in these coun-
tries. In fact, IBD first emerged in Northern 
Europe and North America, followed by the 
rest of Europe, South America and Japan 
(3). The exact etiopathogenesis of IBD is 
still unclear, but the most widely acknowl-
edged mechanism involves an inappropri-
ate interaction between the immune sys-
tem of genetically susceptible individuals, 
the microbiota, and environmental factors 
(4). The standard treatment of IBD is cur-
rently based on the administration of anti-
inflammatory drugs, such as mesalazine 
and corticosteroids, but the treatment 
response rates are suboptimal. Since IBD 
presents as a distortion of the relationship 
between the intestinal microbiota and the 
host response, probiotics and prebiotics 
have been proposed as possible therapeu-
tic agents, since the balance of the intesti-
nal microbiota can also be enhanced with a 
diet of non-digestible substances that can 
selectively promote the growth and/or the 
activity of one or more bacteria already 
present in the gastrointestinal tract or 
taken with probiotics. The probiotics that 
have been tested for the treatment of IBD 
include mainly lactic acid bacteria, such as 
different Lactobacilli and bifidobacteria 
strains. It has been observed that the ad-
ministration of Lactobacilli helps to im-
prove the inflammatory process in IBD (5). 
About 1–2% of colorectal cancer cases have 
a pathological background characterized 
by a chronic inflammation of the intestinal 
mucosa that may evolve to a minor (low-
grade) or a more severe (high-grade) dys-
plasia, which may in turn give rise to a 
carcinoma in situ and finally to an invasive 
carcinoma through neoplastic transforma-
tion. Short-chain fatty acids, in particular 
butyrate, derived from the bacterial fer-
mentation of indigestible carbohydrates, 
provide nutrients and growth signals for 
the intestinal epithelium. Butyrate has been 
shown to prevent apoptosis and the subse-
quent mucosal atrophy in normal colono-
cytes (6). 
 
The intestinal mucosa 
The mucosa surrounding the intestinal 
lumen acts as a physical barrier to the 
bacterial species living in the intestine 
(microbiome), and consists of a single 
layer of epithelial cells. An intact mucosal 
barrier is essential for intestinal wellbeing, 
and rapid healing of this layer following 
injury is crucial for disease prevention. The 
epithelial barrier stops any potentially 
harmful substances from passing into the 
lumen. It also regulates the flow of nutri-
ents, solutes, and ions into the underlying 
mucosa. Molecules can cross the epithe-
lium through the apical plasma membrane 
via specialized channels (transcellular path-
way). They can also pass across the 
paracellular space between epithelial cells 
through the pores created by junction 
proteins (paracellular pathway) (7). The 
mucosal cells are tied to each other by 
different intercellular junctions: Zonula 
Occludens (tight junctions (TJs)) and Zonula 
Adherens (adherens junctions), collectively 
known as the apical junction complex 
(AJC), gap junctions and desmosomes. The 
AJC regulates cell polarity and enables the 
selective permeability barrier function. 
Coordination of the TJ proteins with the 
actin cytoskeleton is required to enable the 
processes of endocytosis and intracellular 
signaling pathways. In addition, commen-
sal bacteria are involved in the mainte-
nance of host barrier homeostasis by 
modulating cell renewal, facilitating wound 
healing, and reorganizing the TJs (8). The 
selective permeability of the barrier is 
determined by claudin proteins and the 
expression patterns of charged amino 
acids in their extracellular loops which 
generate different sized pores through 
which solute transfer occurs. TJ stability 
and dynamic formation to accommodate 
intestinal epithelial cell (IEC) turnover, that 
occurs every four to five days, are essential 
to maintain the integrity of the mucosal 
barrier. Thus, TJ proteins are continuously 
internalized via clathrin-mediated endocy-
tosis. TJ turnover and claudin expression 
can be modified by cytokines released by 
leucocytes migrating across epithelial bar-
riers. In vitro experiments have shown that 
TNF-α downregulates claudin proteins, 
increasing the permeability of the intesti-
nal mucosa. TJ recycling can also be al-
tered by inflammation-inducing pathogenic 
bacteria, causing increased claudin inter-
nalization and enhanced permeability (9). 
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The physiological regulation of barrier 
homeostasis relies on tightly controlled 
signal transduction pathways that con-
verge on the cytoplasmic TJ proteins. 
 
The microbiota 
The intestine of the mammalian fetus is 
sterile while in utero. At birth, the intesti-
nal microbiota is acquired by ingesting 
maternal anal or vaginal organisms (10). 
The effect of the first inoculum may be 
lifelong, regulating the development of the 
immune system and the intestinal microbi-
ota. The bacterial composition of the in-
oculum received at birth and the structure 
of the host’s intestinal epithelium, as well 
as diet, can affect the density and compo-
sition of the microbiota. The intestinal 
microbiota plays a critical role both in 
healthy individuals and progression of 
diseases such as inflammatory bowel dis-
ease and colon cancer. Each individual's 
intestine is colonized by up to 
10
14
 bacterial cells of at least 160 different 
species, that sums up to a population 
about 10 times larger than that of the 
somatic and germ cells harbored by the 
human body (11). The microbiota exerts 
diverse physiological functions such as 
inhibition of pathogenic bacteria and syn-
thesis of short-chain fatty acids; stimula-
tion of nutrient absorption, intestinal im-
mune system and cellular renewal; synthe-
sis of vitamins and amino acids; and the 
decomposition of protein compounds (12). 
A relationship has been discovered be-
tween the microbiota and diseases such as 
obesity and IBD (13). Changes in the mi-
crobiota composition are mainly influ-
enced by diet (14) and age, as well as 
genetic factors (15). Low molecular weight 
metabolites produced by the intestinal 
microbiota play a direct role in the mainte-
nance of intestinal health and in the onset 
of disease. Microorganisms and associated 
genomes are likely to produce compounds 
that directly influence host life processes. 
The beneficial effects of lactic acid-
producing organisms in fermented milk 
products were first discovered in the be-
ginning of the 20
th
 century by Metchnikoff 
(16). Fermented milk products contain 
natural compounds and microorganisms, 
known as probiotics, that are thought to 
be beneficial to human health. The use of 
probiotics to help maintain intestinal ho-
meostasis and ameliorate specific gastro-
intestinal pathologies has generated enor-
mous interest in recent years. Some strains 
of probiotic microbes can reduce intestinal 
permeability through direct effects on the 
IECs and reduce inflammation. IECs have 
signaling mechanisms that activate the 
immune system following various stimuli. 
Nuclear factor-kappaB (Nf-κB) is a transcrip-
tion factor present in the cytoplasm in an 
inactive form, bound to inhibitory mole-
cules of the IκB family (17). In response to 
proinflammatory stimuli, IκB becomes 
phosphorylated and detaches from Nf-κB, 
allowing it to migrate from the cytoplasm 
to the nucleus and begin the activation of 
the transcription of specific genes (18). 
Lactobacillus plantarum has been shown 
to inhibit the degradation of IκB and, con-
sequently, the activity of NF-κB in vitro 
(19). Another molecular target modulated 
by probiotics is PPARγ, a nuclear receptor 
that can regulate the level of intestinal 
inflammation by inhibiting the activity of 
NF-κB; PPARγ has been found in small 
amounts in the IECs of patients with IBD 
(20). Probiotics can implement their benefi-
cial activity through several mechanisms 
(Figure 1). 
 
The short-chain fatty acids 
The short-chain fatty acids (SCFA) are small 
fatty acids, containing one to six carbon 
atoms, with an anionic behavior. They 
derive from the bacterial fermentation of 
polysaccharide, oligosaccharide, and glyco-
protein precursors in the colon (21). The 
fermentation process involves many reac-
tions and metabolic processes leading to 
anaerobic microbial breakdown of organic 
matter that produces energy for microbial 
growth and other metabolic end products 
for host use. The production rates of 
SCFAs vary in the diverse tracts of the 
intestine, depending on the bacterial spe-
cies present in the microbiome and the 
host diet (that is responsible for the avail-
ability of the necessary precursors for the 
production of SCFAs). Bacterial fermenta-
tion and proliferation are highest in the 
proximal colon where substrate availability 
is greatest (22). Since specific species such 
as Bifidobacterium and Lactobacillus have 
been associated with health benefits, it 
would be useful to identify specific bacte-
ria with defined metabolic functions. SCFAs 
are rapidly absorbed by the caecum and 
colon, and have been shown to enhance 
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sodium absorption and bicarbonate secre-
tion. The absorption of SCFAs can take 
place through two mechanisms: diffusion 
of protonated SCFAs and anion exchange. 
The main SCFAs, acetate, propionate and 
butyrate, are absorbed at comparable 
rates in the different regions of the colon. 
SCFAs have several roles: they provide 
nutrients for the colonic epithelium, as 
well as acting as modulators of colonic 
and intracellular pH, and regulators of 
proliferation, differentiation and gene 
expression (23). SCFAs are the main en-
ergy source of colonocytes, and they are 
also fundamental for mucous membrane 
growth control. SCFAs regulate the prolif-
eration of colonic epithelial cells, by not 
only favoring the re-epithelialization of the 
normal mucous membrane, but also by 
preventing the proliferation of tumor cells 
by inhibiting DNA synthesis and re-
establishing natural apoptosis. SCFAs in 
general, and, in particular, butyrate, en-
hance the growth of bacteria such as Lac-
tobacilli and Bifidobacteria, that play a 
very important role in the physiology of 
colonocytes (24). 
 
Butyric acid: production and metabolism 
Butyric acid is a SCFA with four carbon 
atoms that causes the characteristic smell 
of rancid butter. It is also known as bu-
tanoic acid or butyrate, and its formula is 
CH
3
CH
2
CH
2
-COOH. Butyrate is produced 
through a fermentation process involving 
bacteria feeding on prebiotic products in 
anaerobic conditions. The dietary fiber is 
fermented by microbes into butyrate in the 
lumen of the colon, and transported into 
the colonocytes. The absorption of butyric 
acid by colonocytes occurs through various 
mechanisms that change depending on the 
location. On the apical side, the absorption 
takes place through passive diffusion and 
the use of non-ionic transporters like 
monocarboxylate transporter (MCT) type 1 
and sodium-coupled monocarboxylate 
cotransporter (SMCT). On the basolateral 
membrane, there is a carrier-mediated 
HCO
3
 gradient-dependent anion–butyrate 
exchange system. The transport of bu-
tyrate appears to be influenced by the pH 
levels of the intestinal lumen. Butyric acid 
absorption uses a pH-activated, electroneu-
tral anion exchange system that functions 
best at a pH value of 5,5 (25). MCTs cou-
EMBJ, 9(4), 2014 — www.embj.org 
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Figure 1: Microbiota has many roles in the regulation of host processes. It is able to 
change the response of immune cells through mechanisms involving (for example) the 
release of immune-regulatory molecules. It changes the intestinal environment through 
the release of compounds that may modify pH (such as lactic acid) and bacteriocidin to 
inhibit the growth of pathogens. It interacts with colonocytes inducing in them mecha-
nisms to increase tight junctions (higher permeability). Moreover, it produces com-
pounds important for the health of the subject (for example SCFA) and molecules with 
anti-oxidative effects. It competes with the other bacterial species inhabiting the intes-
tine for nutritive substances, adherence and translocation.  
pled with H+ ions are easily saturated and 
can be inhibited by compounds such as 
acetate, propionate, lactate and pyruvate. 
SMCTs function with sodium ion, nicoti-
nate and ketone bodies. This family of 
receptors includes SMCT1 and SMCT2. 
Studies on colon cancer cells have shown 
that these two transporters may play a role 
in tumorigenesis. In fact, in colon cancer 
cells, their expression is silenced and the 
inhibitory effect of butyrate is prevented, 
confirming the theory that these two 
genes act as tumor suppressors (26). The 
relationship between IBD and colon carci-
noma resides in the fact that chronic in-
flammatory diseases (such as IBD) increase 
the risk of developing tumors. Butyrate is 
used by colonocytes primarily as an energy 
source to complete oxidation which yields 
CO
2
 through the fatty acid oxidation path-
way. The microbiome regulates host me-
tabolism, having a strong effect on the 
energy homeostasis of the colon. In fact, 
metagenomic sequence data show that the 
intestinal microbiome is highly enriched in 
genes involved in energy production and 
metabolism. From the results of a com-
parative study on colonocytes derived 
from germfree (GF) and conventional 
(CONV-R) mice (with normal but undefined 
microbiota), it has emerged that colono-
cytes from GF mice subsist in an energy-
deprived state and show a decreased ex-
pression of enzymes that catalyze key 
reactions of the tricarboxylic acid (TCA) 
cycle. This leads to a marked decrease in 
the NADH/NAD+ ratio, oxidative phos-
phorylation, and ATP levels. An analysis of 
the transcriptome of the colonocytes from 
GF and CONV-R mice identified 624 
upregulated genes and 813 downregulated 
genes in GF compared to CONV-R. A pro-
teomic comparative analysis with two-
dimensional shotgun mass spectrometry 
approach did not find significant differ-
ences in the levels of proteins between the 
GF and CONV-R samples. Data analysis 
using the Ingenuity Pathway Analysis (IPA) 
and Kegg (Kyoto Encyclopedia of Genes 
and Genomes) identified genes related to 
butyrate metabolism. Genes linked to β-
oxidation and the TCA cycle are downregu-
lated in GF colonocytes, confirming that 
bacteria exert a positive effect on the 
regulation of these processes. Conse-
quently, there is a marked decrease in 
NADH/NAD+, oxidative phosphorylation, 
and ATP levels. These alterations eventu-
ally lead to the death of colonocytes 
through the autophagy pathway (27).  
 
Bacterial producers of butyric acid 
The majority of butyrate-producing bacte-
ria found in human faeces are highly oxy-
gen-sensitive anaerobes belonging to the 
Clostridial clusters IV and XIVa (28). De-
creased quantities of these bacteria spe-
cies have been reported in the gut of IBD 
patients (29, 30), thus making them poten-
tial probiotic candidates for the treatment 
of IBD. Recently, considerable progress has 
been made in the isolation of these strictly 
anaerobic butyric acid-producing bacteria 
from the human intestine. It has been 
shown that lactic acid, produced in vitro by 
lactic acid bacteria, is used by some Clos-
tridial cluster XIVa species for the produc-
tion of high concentrations of butyric acid 
(28). This mechanism is called cross-
feeding and it could explain why admini-
stration of lactic acid bacteria to IBD pa-
tients can, in certain cases, be beneficial 
due to the stimulation of butyric acid pro-
duction. The ideal probiotic would there-
fore be a colonizing bacterium that com-
bines systemic anti-inflammatory and im-
munoregulatory effects with delivery of 
high butyrate levels at the site of action, 
and that can be ingested in a stable form, 
such as spores. One potential problem is 
that bowel conditions in IBD patients may 
not be optimal to support the growth of 
these bacterial species. However, butyrate 
producers present in the colon are phy-
logenetically diverse and it has not been 
investigated in detail to date which specific 
species are decreased in IBD. Therefore, it 
is likely that strains with good colonizing 
properties can be identified. Furthermore, 
a symbiotic approach, using a prebiotic in 
combination with a butyrate producer, may 
help to reestablish such bacteria in indi-
viduals affected by IBD. Strains of Clos-
tridial clusters IV and XIVa have been 
found to be highly successful in decreasing 
inflammation and necrosis in rodent IBD 
models. Indeed, Faecalibacterium praus-
nitzii, a species belonging to cluster IV, has 
been shown to be much less prevalent in 
the intestinal microbiota of IBD patients. 
This species showed great promise in 
counterbalancing dysbiosis in a mouse IBD 
model (31). 
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The effects of butyric acid on the health 
of colonocytes 
It has been observed that patients with UC 
appear to have impaired butyrate metabo-
lism. Butyrate enemas have been demon-
strated to ameliorate inflammation in UC 
(32). Butyric acid, produced within the 
intestinal lumen by bacterial fermentation 
of dietary carbohydrates, has a wide vari-
ety of effects on intestinal functions. 
Firstly, butyric acid is the preferred source 
of energy of colonocytes. It also has vari-
ous effects on colonocyte proliferation, 
differentiation and apoptosis, in addition 
to anti-inflammatory effects. Butyric acid 
can influence gene expression, since has 
been reported to interact with histone 
deacetylase (HDAC) and inhibit it. This 
results in hyperacetylation of histones with 
a consequent suppression of Nf-κB activa-
tion. Butyric acid reinforces the colonic 
defense barrier by increasing production 
of mucins and antimicrobial peptides. 
Moreover, it has been shown that butyric 
acid decreases intestinal epithelial perme-
ability by increasing the expression of 
tight junction proteins. Anti-inflammatory 
actions, combined with a strengthening 
effect on the mucosal barrier integrity, are 
ideal properties for therapeutic com-
pounds against IBD-like syndromes. In-
deed, it has been shown that butyrate can 
yield positive results in the treatment of 
active UC (33). Therefore, butyric acid has 
a potential therapeutic effect against IBD, 
but the actual delivery into the gut is still 
problematic. Several mechanisms are pos-
sible. Fermentation of dietary fiber leads 
to butyrate production. An increase in 
butyrate production may result from a 
direct stimulation of butyrate producers or 
indirect actions such as metabolic cross-
feeding of fermentation products from 
other bacterial groups (34). Butyrate has 
been shown to protect Caco-2 cell 
monolayers from Campylobacter jejuni 
invasion and translocation in a concentra-
tion-dependent manner by increasing the 
transepithelial electrical resistance (TEER), 
implying a decrease in the permeability of 
intestinal mucosa (35). The effects of bu-
tyrate have been investigated in a study of 
intestinal biopsy specimens, lamina pro-
pria mononuclear cells (LPMC) and periph-
eral blood mononuclear cells (PBMC) de-
rived from 17 patients affected by CD. 
Butyrate treatment was found to induce a 
decrease in TNF production and proinflam-
matory cytokine mRNA expression in intes-
tinal biopsies and LPMC of CD patients. 
PBMC were cultured in the presence or 
absence of lipopolysaccharide (LPS) and 
the effects of treatment with butyric acid 
were evaluated. The results showed a de-
creased expression of proinflammatory 
cytokines in PBMC and transmigration of 
NF-κB from the cytoplasm to the nucleus, 
while IκBα levels remained stable (36). CD 
and UC epithelia have been shown to be 
subjected to metabolic stress, leading to a 
decreased TEER and an increased number 
of pseudopodia, that is consistent with the 
results showing increased internalization 
and translocation of bacteria across mu-
cosa (especially E. coli). Butyrate is able to 
significantly reduce the bacterial transloca-
tion across epithelia treated with Dinitro-
phenol (DNP), but does not ameliorate 
TEER in monolayers exposed to DNP+E. 
coli. Inhibition of bacterial transcytosis 
across metabolically stressed epithelia has 
been found to be associated with reduced 
inhibitory protein I-κB phosphorylation 
and, hence, NF-κB activation (37). The gut 
microflora in some patients with CD can 
contain reduced in numbers of butyrate-
producing bacteria, and this might result 
in metabolic stress for the colonocytes. 
Diets containing fermentable fibers and 
resistant starches lead to a shift in the host 
intestinal microbiome, increasing the pro-
portion of butyrate-producing bacteria, and 
consequently butyrate production. Thus, 
increasing the butyrate production should 
also enhance the protection of the epithe-
lium through strengthening the mucosal 
barrier through increased TJ protein pro-
duction and TEER, as well as through de-
creased permeability and bacterial translo-
cation (Figure 2). Similarly, a diet contain-
ing probiotic bacteria should in time boost 
barrier function and integrity. It has there-
fore been hypothesized that butyrate is 
important in the maintenance and regula-
tion of the barrier function of the colonic 
epithelium. It also protects human colon 
cells from DNA damage through its ability 
to stimulate the expression of glutathione 
S-transferases, a multigene family of en-
zymes mainly involved in the detoxification 
of chemicals. At a molecular level, butyrate 
has also been shown to affect gene expres-
sion through the phosphorylation and 
acetylation of histone proteins, particularly 
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H3 and H4. Hyperacetylation of histones 
disrupts ionic interactions with the adja-
cent DNA backbone, creating less densely 
packed chromatin, or euchromatin, and 
allowing the transcription factors to acti-
vate specific genes (6). Data obtained from 
studies conducted on Caco-2 cell lines 
treated with 2mmol/L of butyrate in the 
culture medium suggest that it may be 
able to strengthen the tight junction bar-
rier in IBD by increasing the expression of 
the claudin-2, occludin, cingulin and 
zonula occludens poteins (ZO-1, ZO-2) 
(38).  
 
Pathogenesis of IBD: the role of Heat 
shock proteins 
Heat shock proteins (Hsps) are proteic 
complexes involved in processes like fold-
ing, refolding, translocation and degrada-
tion of intracellular proteins under normal 
and stress conditions (39). Hsps are also 
involved in other processes, such as inter-
actions with the immune system. In fact, 
when these proteins are released in the 
extracellular environment, they can trigger 
an inflammatory response (40), since Hsps 
are highly conserved molecules that pre-
sent sequences similar to bacterial and 
human orthologs (molecular mimicry). 
Through this mechanism Hsps can stimu-
late both innate and adaptive immune 
responses, becoming primary targets of 
the autoimmune response (41). For this 
reason, Hsps are thought to be involved in 
the pathogenesis of a number of chronic 
inflammatory and autoimmune diseases, 
such as rheumatoid arthritis, myasthenia 
gravis, and IBD (42). Hsps have been found 
to be increased in both tissues and serum 
of patients with UC, and various mecha-
nisms of action have been hypothesized 
for these proteins. In a situation of cellular 
stress (like in IBD), in which the cell needs 
to produce much more proteins than under 
normal conditions, Hsps levels increase 
(since they are involved in the folding of 
newly generated proteins) may reflect an 
antipathogenic mechanism that could be 
used as a biomarker to assess prognosis 
and response to the treatment. Another 
mechanism of action may be explained by 
the molecular mimicry of Hsps with foreign 
components (such as GroEL in the bacteria 
of intestinal microflora) that can trigger a 
response against self Hsps. This situation 
leads to the formation of antibody-Hsp 
complexes that can set off the inflamma-
tion process typical of IBD (43). Some as-
pects of the role played in IBD pathogene-
sis by molecular chaperones interacting 
with components of the immune system 
involved in inflammation still remain un-
clear. Thus, we still need to understand 
exactly why and how inflammation devel-
ops and is maintained through periods of 
relapse and remission. Hsp chaperones 
such as Hsp70, Hsp60 and Hsp10 play a 
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Figure 2: Butyric acid increases TEER through a mechanism that involves an increased 
production of the proteins that form Tight Junctions. In this way, the permeability of the 
mucosa is reduced,  resulting in decreased translocation of bacteria through the muco-
sal barrier.  
critical role in the inflammatory response 
to a number of noxae or stressors and in 
immune regulation (44). It could therefore 
be useful to revisit CD and UC under the 
light of this new information in order to 
fully understand all the aspects of the 
involvement of Hsp chaperones in these 
diseases and their role in the pathogenesis 
of such conditions. The roles of the chap-
eronins Hsp60 and Hsp10 have already 
been studied relatively extensively. Both 
were traditionally considered intracellular 
molecules, confined to the mitochondria 
and dedicated to assisting protein folding. 
However, in the last few years Hsp60 and 
Hsp10 have been found in other locations 
outside the mitochondria, such as the 
cytosol, cell membrane, intercellular 
space, and blood (45, 46). It has been 
demonstrated that mucosal Hsp60 de-
creases in UC patients treated with combi-
nation therapies (mesalazine+probiotics), 
suggesting that this chaperonin could be a 
reliable biomarker for monitoring re-
sponse to the treatment, and that it might 
play a role in the pathogenesis of this 
disease (47). A study on mucosal biopsies 
obtained from 40 patients with mildly to 
moderately active UC without systemic 
comorbidities analyzed changes in Hsp10, 
Hsp70 and Hsp90 levels and localization in 
the epithelium and lamina propria. Sam-
ples were obtained at diagnosis and after 
therapy. Patients were treated for a period 
of six months with 1.2 or 2.4 g/die 
(depending on disease severity) of mesa-
lazine (a drug composed of 5-ASA linked 
to sulfapyridine via a diazo bond that is 
cleaved by bacterial azoreductases in the 
colon to release the two components (48)) 
or with a combination of mesalazine and 1 
capsule/die of probiotics (Acronelle®, 
Bromatech, Milan, Italy). Analysis of 
Hsp10, Hsp70 and Hsp90 levels and local-
ization was performed with immunohisto-
chemistry. The results showed that Hsp 
levels changed significantly after therapy: 
Hsp10 decreased in both the epithelium 
and the lamina propria in the mesalazine 
group and the mesalazine+probiotics 
groups; Hsp70 decreased only in the epi-
thelium of the mesalazine and the mesa-
lazine+probiotics groups, and Hsp90 de-
creased only in the lamina propria of the 
mesalazine+probiotics group (49). Thus 
the levels of Hsp10, Hsp70 and Hsp90 are 
increased in UC patients at the time of 
diagnosis and decrease with therapy, sup-
porting the notion that these proteins 
should be taken into consideration in the 
study of the mechanisms that promote the 
development and maintenance of IBD, and 
as biomarkers of this disease (e.g. to moni-
tor response to treatment at the histologi-
cal level).  
 
Effects of butyric acid on Hsp expres-
sion in colonocytes 
Butyric acid is a modulator of growth, func-
tion, and differentiation of intestinal epi-
thelia (50). It arises from bacterial fermen-
tation of undigested or malabsorbed die-
tary carbohydrates. When IECs come into 
contact with heat, osmotic, oxidative, or 
other stresses, butyric acid can stimulate 
the activation of a “stress tolerance” sys-
tem based on the induction of cytoprotec-
tive Hsps. Among these proteins there are 
Hsp25 (involved in the stabilization of the 
actin cytoskeleton), Hsp72 (highly stress-
inducible) and Hsp73 (constitutive) in-
volved in the prevention of cell denatura-
tion (51). These Hsps help to maintain 
efficient tight junctions between IECs, thus 
promoting the function of the mucosa. A 
study investigating the effects of three 
different kinds of diets in rats [cellulose 
free, normal and pectin-enriched (to en-
hance the production of butyric acid in the 
colon)] found differences in the genic ex-
pression of the three groups, and conse-
quently, in their proteomic assets. Western
-blot analysis of Hsp25, Hsp72 and Hsp73 
found an increase in the Hsp25 levels in 
the colonic mucosa derived from rats fed 
with a pectin-based diet, but no differences 
were found in the levels of Hsp72 and 
Hsp73 between the groups (52). Some 
studies have suggested that the Hsp25-
mediated cytoprotective effect involves 
cytoskeletal stabilization or protection of 
critical cellular proteins (53). How butyrate 
and other SCFAs induce Hsp25 expression 
is not known. Butyrate can inhibit histone 
deacetylase, causing changes in the his-
tone that may modulate gene transcription 
rates (54). Butyrate can also alter gene 
transcription rates through the activation 
of specific DNA sequences that are puta-
tive butyrate response elements 
(transcriptional binding domains of ap-
proximately 11–13 base pairs) (55). A 
study on rats with a dextran sodium sul-
fate (DSS)-induced UC treated with butyrate 
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showed a significant protective effect of 
the acid against the decrease in cell viabil-
ity, with an increase in mucosal permeabil-
ity and polymorphonuclear neutrophil 
infiltration. It has also been shown that 
butyrate inhibits Hsp70 expression in DSS 
colitis, and the activation of HSF (a tran-
scription factor involved in the expression 
of Hsp genes) and Nf-kB. Butyrate enema 
was therefore found to be cytoprotective 
in DSS colitis, an effect partly mediated by 
suppressing the activation of Hsp70 and 
Nf-kB (32).  
 
Conclusions 
Butyric acid is a SCFA with multiple effects 
on the physiological activities of colono-
cytes. Together with all the considerations 
discussed in this review, this particular 
clearly shows the importance of studying 
the metabolic patterns of multifactorial 
diseases like IBD. In fact, recently it has 
been considered important to analyze the 
problems related to human diseases with 
an integrated approach rather than the 
traditional reductionist approach used 
until now. In fact, this can be considered 
the era of “omic” sciences such as Genom-
ics, Proteomics, Trascriptomics, Interac-
tomics and Metabolomics. Butyric acid 
derived from bacterial fermentation is 
used by colonocytes primarily as an energy 
source, but it can also influence gene 
expression since it is able to inhibit HDAC. 
This epigenetic phenomenon can influence 
the production of proteic factors such as 
proinflammatory factors (Nf-κB) and Hsps. 
The latter can promote protective effects 
(Hsp25 stabilizes the actin cytoskeleton) 
or interact with the immune system, induc-
ing an autoinflammatory response (like 
Hsp60). At this time, butyric acid is used 
as a coadjuvant in the treatment of IBD, 
since it has shown anti-inflammatory ef-
fects on the mucosa of the colon. More-
over, it has been reported that butyric acid 
is able to induce the production of cyto-
protective Hsps (like Hsp25 and Hsp72) 
and to inhibit the production of some 
Hsps, such as Hsp70 (that may play a role 
in the progression of the disease patho-
genesis). Butyrate is able to support 
colonocytes primarily as an energetic sub-
strate, moreover increasing the expression 
of tight junction proteins and determining 
an amelioration of the general state of 
inflamed mucosa in IBD (by decreasing 
mucosal permeability), in addition to hav-
ing well documented anti-inflammatory 
properties. Considering the multiple roles 
played by butyric acid in the physiology of 
colonocytes, it may be seen as a valid sup-
plementary therapy for IBD to improve the 
general condition of the mucosa. This is a 
highly current topic, subject of continued 
interest in the international literature. 
Further clinical trials are necessary to bet-
ter define the biomolecular dynamics in-
volved in the decrease of intestinal phlo-
gosis in patients with IBD.  
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